Table 1

Patient characteristics.

Characteristic No. of Patients
Evaluable patients 100
Age (median, range) 62.3 (63.0, 22-88 years)
Follow-up a (median, range) 29.7 (24.1, 0.01-108 months)
FIGO stage:
1a 4 (4%)
1b 1 (1%)
1c 3 (3%)
IIb 2 (2%)
IIc 4 (4%)
IIIa 1 (1%)
IIIb 2 (2%)
IIIc 76 (75%)
IV 7 (7%)
Histology:
Papillary serous 73 (73%)
Clear cell 7 (7%)
Endometrioid 5 (5%)
Mucinous 2 (2%)
Undifferentiated 3 (3%)
Other (transitional, mixed, carcinosarcoma) 10 (10%)
Grade:
1 7 (7%)
2 9 (9%)
3 84 (84%)
Response to frontline therapy:
Complete response 52 (52%)
Partial response 41 (41%)
Progression 1 (1%)
Unknown 6 (6%)
Recurrences
Recurrence/persistent disease 62 (62%)
Current status:
Alive with no evidence of disease 35 (35%)
Alive with disease 31 (31%)
Died of disease 31 (31%)
Died from other causes 3 (3%)
CT Antigen status (RT-PCR)
SCP-1 positive 15/100 (15%)

a The median survival for all patients was 57 months (CI 26-88 months).